Opendata, web and dolomites

SilkFUSION SIGNED

Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SilkFUSION project word cloud

Explore the words cloud of the SilkFUSION project. It provides you a very rough idea of what is the project "SilkFUSION" about.

cells    immunologically    supply    environment    fold    stem    innovative    correct    genetically    fviia    medical    mks    drugs    marrow    transfusions    pathogenetic    bone    conflict    platelets    platelet    optimized    efficacy    ink    live    create    primary    regarding    inherited    vivo    human    reproducible    silkfusion    proteins    molecules    thrombogenic    predicting    dimensional    wounded    megakaryocytes    biochemical    pluripotent    surgery    engineering    technological    disorders    suited    alloimmunised    recombinant    generating    clinicians    demand    silk    vitro    kits    extremely    mechanisms    hpscs    printing    proven    screening    supercharged    plt    therapies    fibroin    haemorrhage    55    therapeutic    model    precision    blood    strategies    ex    release    instruments    acute    biomaterial    transfusion    zones    specialized    prove    reducing    bio    ineffective    massive    functional    plts    humans    engineer    ing    containing    successful    trauma    hypothesis    patients    3d    nanotechnologies    platforms    vision    platform    clinical    gain    thrombocytopenic    chip    physical    affordable    matched    modified    drug    safety    groundbreaking   

Project "SilkFUSION" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI PAVIA 

Organization address
address: STRADA NUOVA 65
city: PAVIA
postcode: 27100
website: www.unipv.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://silkfusion.eu/
 Total cost 2˙998˙500 €
 EC max contribution 2˙998˙500 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-1-2016-2017
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI PAVIA IT (PAVIA) coordinator 738˙327.00
2    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 688˙327.00
3    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 688˙327.00
4    CELLINK AB SE (GOTEBORG) participant 344˙163.00
5    INTEGRATED SYSTEMS ENGINEERING SRL IT (BRUGHERIO) participant 319˙580.00
6    KNOWLEDGE INNOVATION MARKET S.L. ES (BARCELONA) participant 219˙773.00

Map

 Project objective

'The demand for human platelets (plts) for medical research and clinical applications is massive. The primary goal of SilkFUSION is to engineer groundbreaking 3D nanotechnologies for large-scale production of blood plts for human transfusion from human pluripotent stem cells (hPSCs). Our hypothesis is that plt production ex-vivo can be optimized by providing megakaryocytes (Mks) with the correct physical and biochemical environment.

To prove this, we will develop a unique technological platform by engineering non-thrombogenic silk-fibroin biomaterial with proteins, that were proven to promote a 55-fold gain in plt production, to create a three-dimensional ex-vivo bone marrow model that will enhance plt release from Mks derived from hPSCs. Our platform will include (i) novel applications to study pathogenetic mechanisms in patients with inherited platelet production disorders using genetically modified hPSCs; (ii) screening technology for predicting therapeutic efficacy of drugs for thrombocytopenic patients. The development of this technology will exploit an extremely innovative approach using silk-fibroin as a bio-ink for 3D printing a 'live chip' containing viable Mks for reproducible drug testing.

Our long-term vision is to foster the production of plts in-vitro for clinical transfusions in humans at a scale and cost that will address current supply challenges regarding (i) immunologically matched products to alloimmunised patients; (ii) “supercharged” platelets with recombinant FVIIa generating plts specifically suited for patients with acute haemorrhage resulting from trauma, surgery and wounded in conflict zones. The successful development and distribution of the SilkFUSION platforms will also offer researchers and clinicians specialized precision instruments and bio-ink kits for determining the safety and efficacy of drugs, reducing costs of ineffective therapies while promoting affordable functional strategies for the development of novel molecules.'

 Deliverables

List of deliverables.
Public Project website Websites, patent fillings, videos etc. 2020-03-18 18:53:14
Targeted stakeholders identified and informed about the project_12 Documents, reports 2020-03-18 18:53:14
Workshops_12 Documents, reports 2020-03-18 18:53:14

Take a look to the deliverables list in detail:  detailed list of SilkFUSION deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Lorenzo Tozzi, Pierre-Alexandre Laurent, Christian A. Di Buduo, Xuan Mu, Angelo Massaro, Ross Bretherton, Whitney Stoppel, David L. Kaplan, Alessandra Balduini
Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production
published pages: 122-133, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2018.06.018
Biomaterials 178 2020-03-18
2018 Jennifer H. Shepherd, Daniel Howard, Amie K. Waller, Holly Rebecca Foster, Annett Mueller, Thomas Moreau, Amanda L. Evans, Meera Arumugam, Guénaëlle Bouët Chalon, Eleonora Vriend, Natalia Davidenko, Cedric Ghevaert, Serena M. Best, Ruth E. Cameron
Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity
published pages: 135-144, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2018.08.019
Biomaterials 182 2020-03-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SILKFUSION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SILKFUSION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

MAX-BAS (2019)

Magnetic cross-modal brain activity scanner MAX-BAS

Read More  

MAFIn (2019)

Module for Aberration Correction and Fast Volumetric Imaging in a Light Sheet Fluorescence Microscope

Read More  

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More